Takuya Toyonaga, MD, PhD
Associate Research Scientist in Radiology & Biomedical ImagingDownloadHi-Res Photo
Cards
Appointments
Additional Titles
Associate Director of Imaging, Positron Emission Tomography (PET)
Contact Info
Appointments
Additional Titles
Associate Director of Imaging, Positron Emission Tomography (PET)
Contact Info
Appointments
Additional Titles
Associate Director of Imaging, Positron Emission Tomography (PET)
Contact Info
About
Titles
Associate Research Scientist in Radiology & Biomedical Imaging
Associate Director of Imaging, Positron Emission Tomography (PET)Appointments
Radiology & Biomedical Imaging
Associate Research ScientistPrimary
Other Departments & Organizations
Education & Training
- PhD
- Hokkaido University (2017)
- MD
- Hokkaido University (2012)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Takuya Toyonaga's published research.
Publications Timeline
A big-picture view of Takuya Toyonaga's research output by year.
Richard Carson, PhD
Mika Naganawa, PhD
Adam Mecca, MD, PhD
Yiyun Huang, PhD
Jean-Dominique Gallezot, PhD
Ming-Kai Chen, MD, PhD
33Publications
339Citations
Publications
2024
Relationship between neuroimaging and cognition in frontotemporal dementia: An FDG‐PET and structural MRI study
Cayir S, Volpi T, Toyonaga T, Gallezot J, Yang Y, Sadabad F, Mulnix T, Mecca A, Fesharaki‐Zadeh A, Matuskey D. Relationship between neuroimaging and cognition in frontotemporal dementia: An FDG‐PET and structural MRI study. Journal Of Neuroimaging 2024 PMID: 38676301, DOI: 10.1111/jon.13206.Peer-Reviewed Original ResearchAltmetricConceptsMoCA scoresFDG-PETAssociation of cognitionStandardized uptake value ratioMontreal Cognitive AssessmentSignificant positive associationFrontotemporal dementiaPrimary outcome measurePosterior cingulate cortexDecline of cognitive functionYears of ageGM volumeFrontal cortexOutcome measuresCognitive dysfunctionGray matterCognitive AssessmentMoCAAssociated with cognitive dysfunctionFluorodeoxyglucose (FDG)-PETPositive associationMagnetic resonance imagingPartial volume correctionCognitive functionDementiaInvestigating the Relationships of Atrophy and Hypometabolism on Cognitive Decline in Frontotemporal Dementia (P1-9.018)
Cayir S, Yang Y, Volpi T, Sadabad F, Toyonaga T, Gallezot J, Mecca A, Fesharaki-Zadeh A, Matuskey D. Investigating the Relationships of Atrophy and Hypometabolism on Cognitive Decline in Frontotemporal Dementia (P1-9.018). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204352.Peer-Reviewed Original ResearchConceptsAuthor Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 55. PMID: 38472206, PMCID: PMC10933370, DOI: 10.1038/s41531-024-00674-6.Peer-Reviewed Original ResearchIdentifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of 18F-Fluoromisonidazole and 18F-Fluorodeoxyglucose Positron Emission Tomography
Okamoto M, Yamaguchi S, Sawaya R, Echizenya S, Ishi Y, Kaneko S, Motegi H, Toyonaga T, Hirata K, Fujimura M. Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of 18F-Fluoromisonidazole and 18F-Fluorodeoxyglucose Positron Emission Tomography. BioMed Research International 2024, 2024: 2973407. PMID: 38449509, PMCID: PMC10917478, DOI: 10.1155/2024/2973407.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsPositron emission tomographyF-FDGMRNA expressionOverall survivalGlucose metabolismF-FDG positron emission tomographyAssociated with poor overall survivalProtein expressionEmission tomographyGross total resectionPotential key moleculesFluorine-18 fluorodeoxyglucoseHypoxic conditionsDegree of glucose metabolismMolecular mechanisms of glucose metabolismAggressive primary brain tumorPoor overall survivalPrimary brain tumorKey moleculesTotal resectionPreoperative examinationIntratumoral hypoxiaPrognostic valuePoor prognosisBiomarkers of glioblastomaSynaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 42. PMID: 38402233, PMCID: PMC10894197, DOI: 10.1038/s41531-024-00655-9.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSynaptic density lossPositron emission tomographyBinds to synaptic vesicle glycoprotein 2AAssociated with symptom severityParkinson's diseaseHigh-resolution positron emission tomographySynaptic vesicle glycoprotein 2ADuration of illnessPositron emission tomography scanBrain perfusionIllness durationSymptom severitySeverity of symptomsHC groupSubstantia nigraSynaptic densityLiving brainPD individualsClinical insightsDensity lossPD patientsEmission tomographyBrainSynaptic lossSynapse loss
2023
PET Imaging of Rho‐Associated Protein Kinase 2 in A Mouse Model of Alzheimer’s Disease
Zheng C, Nicholson L, Chen B, Toyonaga T, Liu M, Strittmatter S, Carson R, Huang Y, Cai Z. PET Imaging of Rho‐Associated Protein Kinase 2 in A Mouse Model of Alzheimer’s Disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.075782.Peer-Reviewed Original ResearchConceptsAPP/PS1 micePS1 miceWT miceCentral nervous systemTime-activity curvesAlzheimer's diseaseAPP/PS1 transgenic miceAPP/PS1 transgenic AD miceMouse brainAge-matched WT controlsPS1 transgenic miceAPP/PS1Transgenic AD miceDynamic PET imaging dataROCK2 protein expressionAD drug discoveryHigh tracer uptakeMin post injectionPET imaging resultsExpression levelsReference tissue model 2PET imaging dataProtein expression levelsAD miceMouse modelPET Imaging of Rho‐Associated Protein Kinase 2 in A Mouse Model of Alzheimer’s Disease
Zheng C, Nicholson L, Chen B, Toyonaga T, Liu M, Strittmatter S, Carson R, Huang Y, Cai Z. PET Imaging of Rho‐Associated Protein Kinase 2 in A Mouse Model of Alzheimer’s Disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.081695.Peer-Reviewed Original ResearchConceptsAPP/PS1 micePS1 miceWT miceCentral nervous systemTime-activity curvesAlzheimer's diseaseAPP/PS1 transgenic miceAPP/PS1 transgenic AD miceMouse brainAge-matched WT controlsPS1 transgenic miceAPP/PS1Transgenic AD miceDynamic PET imaging dataROCK2 protein expressionAD drug discoveryHigh tracer uptakeMin post injectionPET imaging resultsExpression levelsReference tissue model 2PET imaging dataProtein expression levelsAD miceRegional time-activity curvesMarkerless head motion tracking and event-by-event correction in brain PET
Zeng T, Lu Y, Jiang W, Zheng J, Zhang J, Gravel P, Wan Q, Fontaine K, Mulnix T, Jiang Y, Yang Z, Revilla E, Naganawa M, Toyonaga T, Henry S, Zhang X, Cao T, Hu L, Carson R. Markerless head motion tracking and event-by-event correction in brain PET. Physics In Medicine And Biology 2023, 68: 245019. PMID: 37983915, PMCID: PMC10713921, DOI: 10.1088/1361-6560/ad0e37.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsPoint source studyHead motion correctionSmaller residual displacementMotion correctionIterative closest point (ICP) registration algorithmHead motion trackingSpatial resolutionResidual displacementData-driven evaluation methodHigh spatial resolutionLow noiseMotion trackingStereovision cameraMotion tracking deviceStructured lightEvent correctionBrain positron emission tomography (PET) imagingTracking deviceReconstruction resultsHMT methodPoint cloudsNegative biasReference cloudUMTEvaluation methodDose reduction in dynamic synaptic vesicle glycoprotein 2A PET imaging using artificial neural networks
Li A, Yang B, Naganawa M, Fontaine K, Toyonaga T, Carson R, Tang J. Dose reduction in dynamic synaptic vesicle glycoprotein 2A PET imaging using artificial neural networks. Physics In Medicine And Biology 2023, 68: 245006. PMID: 37857316, PMCID: PMC10739622, DOI: 10.1088/1361-6560/ad0535.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsNeuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein
Stoner A, Fu L, Nicholson L, Zheng C, Toyonaga T, Spurrier J, Laird W, Cai Z, Strittmatter S. Neuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein. Alzheimer's Research & Therapy 2023, 15: 201. PMID: 37968719, PMCID: PMC10647125, DOI: 10.1186/s13195-023-01345-z.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSynapse lossDKI miceTau accumulationBrain immune activationNeural network dysfunctionPhospho-tau accumulationAccumulation of tauNeuronal genesInflammatory markersAD miceAβ levelsPrion proteinDystrophic neuritesImmune activationTau pathologyNeuronal gene expressionAmyloid-β OligomersGliotic reactionNetwork dysfunctionBehavioral deficitsSynaptic failureAD modelMemory impairmentAlzheimer's diseaseFunction of age